UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 3,570 Shares of CARGO Therapeutics, Inc. (NASDAQ:CRGX)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of CARGO Therapeutics, Inc. (NASDAQ:CRGX) by 31.7% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 14,832 shares of the company’s stock after purchasing an additional 3,570 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in CARGO Therapeutics were worth $214,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of the stock. RTW Investments LP grew its position in shares of CARGO Therapeutics by 0.6% in the 4th quarter. RTW Investments LP now owns 4,124,859 shares of the company’s stock valued at $59,480,000 after buying an additional 25,904 shares during the last quarter. Janus Henderson Group PLC raised its position in shares of CARGO Therapeutics by 5.8% during the fourth quarter. Janus Henderson Group PLC now owns 2,830,544 shares of the company’s stock worth $40,859,000 after acquiring an additional 155,259 shares during the last quarter. Wellington Management Group LLP lifted its stake in shares of CARGO Therapeutics by 7.2% in the fourth quarter. Wellington Management Group LLP now owns 2,190,811 shares of the company’s stock worth $31,591,000 after acquiring an additional 148,088 shares during the period. Red Tree Management LLC acquired a new position in shares of CARGO Therapeutics in the fourth quarter worth approximately $30,293,000. Finally, Vanguard Group Inc. boosted its holdings in CARGO Therapeutics by 1.1% in the fourth quarter. Vanguard Group Inc. now owns 2,084,515 shares of the company’s stock valued at $30,059,000 after acquiring an additional 22,286 shares during the last quarter. 93.16% of the stock is owned by institutional investors.

CARGO Therapeutics Stock Performance

NASDAQ:CRGX opened at $4.48 on Friday. CARGO Therapeutics, Inc. has a fifty-two week low of $3.00 and a fifty-two week high of $25.45. The company has a 50 day simple moving average of $4.30 and a two-hundred day simple moving average of $7.53. The company has a market capitalization of $206.57 million, a PE ratio of -1.05 and a beta of 0.31.

About CARGO Therapeutics

CARGO Therapeutics, Inc, a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies.